What is renal denervation? Medtronic Coronary and RDN President Jason Weidman explains

Jason Weidman is a Medtronic SVP and president of its coronary and renal denervation business. [Photo courtesy of Medtronic]

As Medtronic (NYSE:MDT) continues clinical trials of its Symplicity Spyral renal denervation (RDN) system for treating hypertension, the Fridley, Minnesota-based medical device maker now hopes to win FDA approval in 2023.

To better understand the technology behind what Medtronic leaders expect to become a multibillion-dollar business, Medical Design & Outsourcing spoke with Jason Weidman, Medtronic senior vice president and president of the coronary and renal denervation business, which is part of Medtronic’s cardiovascular portfolio. (We’ve edited this conversation for brevity and clarity.)

MDO: What’s the simplest way to explain renal denervation?

Weidman: The basic idea is that your kidneys are part of the body’s blood pressure control mechanis…

Read more
  • 0

Catheter & Medical Design and VitalDyne Medical rebrand as VitalPath

Catheter & Medical Design and VitalDyne Medical — makers of complex medical catheter systems — have rebranded under the name VitalPath.

The move comes about five months after CMD’s March 2021 acquisition of VitalDyne.

The Roseville, Minn.–based company also has a new website at vitalpath.com. VitalPath will exhibit at booth  No. 1714 at MD&M West, Aug. 10-12, 2021 in Anaheim, Calif.

Get the full story on our sister site Medical Tubing + Extrusion. 

Read more
  • 0

Catheter & Medical Design acquires VitalDyne Medical

Catheter and Medical Design today announced that it has acquired VitalDyne Medical for an undisclosed amount.

Through the acquisition, Catheter and Medical Design takes ownership of VitalDyne’s laser cutting, welding, micromachining and finished device manufacturing capabilities to complement its existing complex catheter shaft design and manufacturing capabilities.

Get the full story on our sister site, Medical Tubing + Extrusion.

Read more
  • 0